CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

Investigational

Approval Year

Substance Class	Protein Created by `admin` on `Sat Dec 16 15:13:02 GMT 2023` Edited by `admin` on `Sat Dec 16 15:13:02 GMT 2023`
Protein Sub Type
Sequence Type	COMPLETE
Record UNII	PW7453NX3R
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

Common Name

English

POMULMERAN EXPRESSED ABCC7 PROTEIN

Common Name

English

CHANNEL CONDUCTANCE-CONTROLLING ATPASE

Common Name

English

CAMP-DEPENDENT CHLORIDE CHANNEL

Common Name

English

ATP-BINDING CASSETTE SUB-FAMILY C MEMBER 7

Common Name

English

CFTR

Common Name

English

ABCC7

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

63891

Created by admin on Sat Dec 16 15:13:03 GMT 2023 , Edited by admin on Sat Dec 16 15:13:03 GMT 2023

Code System Code Type Description

UNIPROT

P13569

Created by admin on Sat Dec 16 15:13:03 GMT 2023 , Edited by admin on Sat Dec 16 15:13:03 GMT 2023

PRIMARY

FDA UNII

PW7453NX3R

Created by admin on Sat Dec 16 15:13:03 GMT 2023 , Edited by admin on Sat Dec 16 15:13:03 GMT 2023

PRIMARY

Glycosylation Type

HUMAN

Glycosylation Link Type	Site
N	1_894
N	1_900

Related Record Type Details


					T5WV2JH7PN

VPO-227

INHIBITOR -> TARGET

Qualification:

IC50

Amount:


					COM1POP492

Vanzacaftor

MODULATOR->TARGET

Amount:


					AW2ZDE8CAS

POMULMERAN

GENE REPLACEMENT->TARGET

Amount:


					1Y740ILL1Z

IVACAFTOR

ACTIVATOR -> TARGET

Amount:


					AW2ZDE8CAS

POMULMERAN

VECTOR->EXPRESSED PROTEIN

Amount:


					SHA6U5FJZL

DEUTIVACAFTOR

ACTIVATOR -> TARGET

Amount:


					T2U4ZA62U4

NESOLICAFTOR

MODULATOR->TARGET

Amount:


					W2F2XU189O

NAVOCAFTOR

ACTIVATOR -> TARGET

Amount:


					AMB0BO0WFH

Icenticaftor

ACTIVATOR -> TARGET

Amount:


					2G3T6M1AS9

DIROCAFTOR

ACTIVATOR -> TARGET

Comments:

PTI-808 is a small molecule “potentiator” that is intended to rescue mutant cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel activity. The Sponsor intends to develop PTI-808 as part of a triple combination therapy with PTI-801 (CFTR “corrector”) and PTI-428 (CFTR “amplifier”) in cystic fibrosis patients

Amount:


					QQF931PRWK

HUMAN PLACENTAL TISSUE

TISSUE EXPRESSION->TRANSPORTER

Qualification:

APICAL

Amount:

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT	CHEMICAL
Molecular Formula	CHEMICAL